Archives
-
Sulfo-Cy5 NHS Ester: Evidence and Scope
2026-10-14
APExBIO describes Sulfo-Cy5 NHS ester, also termed Sulfo-Cyanine5 Succinimidyl Ester, as a sulfonated, water-compatible amine-reactive fluorescent labeling reagent. The catalog supports a conceptual link between covalent biomolecule labeling and far-red fluorescence measurements, but it does not provide an identity-matched research paper, comparative performance data, sample sizes, uncertainty estimates, or independent validation of the cited VLA-4 imaging example.
-
Glabridin–Gold(I), ROS, and Antitumor Immunity
2026-10-14
A 2025 study reports that a glabridin–gold(I) complex, designated 6d, may reshape the liver-cancer immune microenvironment through TrxR- and MAPK-associated mechanisms. The findings are promising but remain preclinical, and a dihydroethidium-based ROS signal should be treated as a probe-dependent readout rather than standalone proof of mechanism or therapeutic benefit.
-
BAY-826 and Müller Cell–Mediated Retinal Survival
2026-10-13
Younis and colleagues report that angiopoietin signaling in Müller cells influences retinal neuron survival through a Tie-2–PI3K/Akt–PEDF/PEDF-R axis. The study supports a mechanistic model in cell-based systems, but it does not establish that BAY-826 was used, nor does it demonstrate a therapeutic effect in patients or intact human retina.
-
AQP9, ZHX2 and KRASG12V Colorectal Cancer
2026-10-13
A 2025 Scientific Reports study links KRASG12V colorectal cancer with reduced AQP9 expression, more aggressive clinicopathological features and altered proliferation–apoptosis balance. Its findings support a possible ZHX2–AQP9 regulatory relationship, but the evidence remains largely associative and cell-based, so therapeutic and clinical implications are hypothesis-generating rather than established.
-
Thermal Shifts and the Limits of Ligand Discovery
2026-10-12
A 2025 review supports thermal shift assays as a useful but indirect approach for investigating ligands of bacterial sensor proteins. The evidence does not establish that the DiscoveryProbe™ Bioactive Compound Library Plus has been validated for this purpose, so catalog claims and review-level findings should remain clearly separated.
-
IDH2, α-KG and HIF-1α in Colorectal Cancer
2026-10-12
A 2024 study examines how IDH2-associated metabolic reprogramming may support colorectal cancer progression through α-ketoglutarate availability, mitochondrial energy production, glycolysis and HIF-1A signaling. The findings support a mechanistic model, but the evidence remains preclinical and does not establish clinical benefit or validate any specific metabolic product.
-
Bazedoxifene and IL-6/GP130 Signaling in Cancer
2026-10-10
Shi and colleagues present a literature-based assessment of bazedoxifene as a potential anticancer agent that disrupts IL-6/GP130 signaling, a pathway linked to tumor survival, proliferation, inflammation, and treatment resistance. The review’s main translational contribution is to connect drug repurposing with a mechanistic strategy focused on GP130-associated signaling while emphasizing that current evidence remains largely preclinical and requires disease-specific validation.
-
Rucaparib (AG-014699): PARP1 Evidence Guide
2026-10-09
Rucaparib, also called AG-014699, is a PARP inhibitor used in DNA damage response and cancer biology research. Evidence supports PARP1 catalytic inhibition and context-dependent DNA-repair vulnerabilities, while transport, assay provenance, model selection, and the preclinical status of some findings limit broad interpretation.
-
Artemisia argyi Oil and Brown Fat Thermogenesis
2026-10-09
A 2025 npj Science of Food study reports that Artemisia argyi oil reduced high-fat diet-associated weight gain and adiposity in a preclinical model while improving insulin sensitivity. Its central mechanistic contribution is the proposed connection between brown adipose tissue thermogenesis, Ucp1 transcription, ZFP516 expression, and ZFP516–LSD1 interaction.
-
PKH26 Red Fluorescent Cell Linker Kit Overview
2026-10-08
A catalog-level overview of the PKH26 Red Fluorescent Cell Linker Kit, including its documented identity, intended conceptual scope, and evidence limitations.
-
PVX Nanoparticles for RNA Gene Delivery
2026-10-08
A 2025 Scientific Reports study presents potato virus X coat protein as a modular scaffold for assembling nucleoprotein nanoparticles around mRNA and circRNA. The work demonstrates tunable particle architectures and reporter-protein expression in eukaryotic cells, while leaving important questions about biodistribution, safety, durability, and therapeutic performance unresolved.
-
Macrophage MERTK in Pressure Overload Heart Failure
2026-10-07
A 2025 study identifies macrophage MERTK as an unexpected amplifier of pressure overload-induced cardiac hypertrophy and heart failure. Its evidence connects efferocytosis of apoptotic cardiomyocytes with mitochondrial RNA–TLR3–IFN-β signaling, revealing a context-dependent inflammatory mechanism that may refine cardiovascular remodeling research.
-
Influenza Hemagglutinin (HA) Peptide: Evidence Overview
2026-10-07
A source-grounded overview of the HA tag peptide as a molecular biology reagent, with conceptual applications in protein detection and affinity studies, alongside a critical assessment of recent findings on PRKX, PD-L1 and immunotherapy resistance in gastric cancer.
-
Removing Pollen Interference in EEM Bioaerosol Detection
2026-10-06
Zhang et al. investigated how pollen fluorescence can confound the classification of hazardous bioaerosol components using excitation–emission matrix spectroscopy. Their combination of spectral transformation and random forest classification improved the reported accuracy to 89.24%, while also clarifying the limits of fluorescence-based recognition in complex environmental samples.
-
ABT-263 and Senolytic Apoptosis Research
2026-10-06
ABT-263, also known as Navitoclax, is a Bcl-2-family inhibitor used in cancer biology and apoptosis research. This overview examines its relevance to therapy-induced senescence, emphasizing findings from a prostate cancer study, evidence strength, conceptual applications, and limits on translating cell-model results into clinical conclusions.